~~<i id='DFDEEF7EC9'><strike id='DFDEEF7EC9'><tt id='DFDEEF7EC9'><pre id='DFDEEF7EC9'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

fashion

author：hotspot 2025-10-02 22:15:29 - browse：881

The Roche booth at ESMO in Madrid. — Roche's booth at the 2023 ESMO conference. Andrew Joseph/STAT

MADRID — A Roche drug lowered the risk of recurrence or death by 76% versus chemotherapy for patients with a type of early non-small cell lung cancer, according to data from a Phase 3 trial presented Saturday.

The findings, which Roche is planning to submit to regulators, could give patients with early-stage ALK-positive cancers another option. The standard treatment after surgery for these patients is chemotherapy.

The results from the Alina trial were presented here at the annual meeting of the European Society for Medical Oncology.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Opioid cravings were reduced by anti

explore

hotspot

entertainment

knowledge

explore

focus

AdobeAPittsburghartificialintelligencestartupemergingasachallengertoMicrosoft’sclinicalnotetakingbus

WSS

Secretariat’s lessons for human medicine

New CMS data security rules will hurt Medicare, Medicaid research

How climate

Flagship Pioneering startup Sonata Therapeutics lays off 21

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Hospital price transparency does save money, advocate argues

focus

fashion

explore

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Medicare Advantage enrollment hits roughly 33.4 million

Sports medicine is finally prioritizing gender equality

Medicare Advantage enrollment grows 7.1% to 33.4 million people

United colonoscopy coverage change 'may cost lives,' doctors say

Secretariat’s lessons for human medicine

FDA approval of Sarepta Duchenne genetic therapy gives me hope

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

Dobbs anniversary: the lost opportunity of abortion as health care

Medicare Advantage enrollment hits roughly 33.4 million

hotspot

As AI regulations shape up, health tech startups beg for clarity

In 'major milestone,' FDA approves first cell therapy for solid tumors

FDA gives detailed accounting of AI

2023 STAT Wunderkinds: get to know the winners

The EU Joint Clinical Assessment needs to live up to its promise

First Opinion Podcast: Long Covid needs a new approach

entertainment

knowledge

explore

focus